Angela Huttner, Selidji Todagbe Agnandji, Olivier Engler, Jay W Hooper, Steve Kwilas, Keersten Ricks, Tamara L Clements, Hulda R Jonsdottir, Sravya Sowdamini Nakka, Sylvia Rothenberger, Peter Kremsner, Roland Züst, Donata Medaglini, Tom Ottenhoff, Ali M Harandi, Siegrist Ca
OBJECTIVES: To report five-year persistence and avidity of antibodies produced by the live-attenuated recombinant vesicular stomatitis virus (rVSV) expressing the Zaire Ebolavirus (ZEBOV) glycoprotein (GP), known as rVSV-ZEBOV (Ervebo®). METHODS: Healthy adults vaccinated with 300,000 or 10-50 million plaque-forming units of rVSV-ZEBOV in the WHO-coordinated trials of 2014-5 were followed for up to four (Lambaréné, Gabon) and five (Geneva, Switzerland) years...
September 1, 2023: Clinical Microbiology and Infection